NovoCure Limited announced top-line results from its Phase 3 TRIDENT trial, which failed to demonstrate a statistically significant improvement in the primary endpoint of overall survival for the Early Start Arm compared to the Maintenance Start Arm. In the intent-to-treat population, the Early Start Arm had a median overall survival of 17.7 months versus 17.5 months (HR 0.953; p=0.519). TTFields therapy was well-tolerated with no new safety signals. NovoCure Limited is a medical technology company that develops and commercializes TTFields therapy for brain tumors.
